Navi Mumbai, Maharashtra -- (SBWire) -- 12/23/2011 --Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug. http://www.bharatbook.com/detail.asp?id=220380&rt=Acute-Myeloid-Leukemia-Therapeutics-Market-2010-2020-Pipeline-Assessment-Market-Forecast-in-G8-Countries.html
This report studies the market from 2010 to 2020 covering seven major regimens and single drugs (off-patent and pipeline) for acute myeloid leukemia treatment. At present, there are four regimens in the market; namely DC regimen used for induction purpose, DC regimen for elderly patients, VCD, and AVD regimen. Plus, there is a drugs named Cytarabine in the market. Growing population of acute myeloid leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 28.4% from 2015 to 2020. North America was the major contributor to this market; accounting for 68.62% of the total sales of acute myeloid leukemia drugs in 2010; whereas AVD regimen was the major regimen accounting for 54.08% of the total sales of acute myeloid leukemia drugs in 2010. Cytarabine drug is also highly effective in the treatment of acute myeloid leukemia that captured the highly market share of AML market in 2010. Acute myeloid leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area. market research reports
The report studies four existing regimens and single drugs for acute myeloid leukemia market. Currently, there are four major drugs in pipeline for acute myeloid leukemia; which are expecting a market launch by 2012-2014. Quizartinib is currently in phase II pivotal clinical trial for the relapsed/refractory AML patient; which will be launched in the market in 2012 by Ambit Biosciences Inc. Quizartinib has received Orphan Drug designation grant from U.S. FDA and European Union. Besides, the drug has obtained fast track designation in the United States in 2010 for the treatment of FLT3-ITD positive patients with relapsed/refractory AML. The drug is expected to be priced at $25,448 for patients who take them annually.
Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to September 2011.
Clinical trials form a major growth strategy in the acute myeloid leukemia therapeutics market; accounting for 39% share between January 2008 and September 2011, followed by collaborations and agreements strategy with a 25% share, and approvals with a 18% share.
Cephalon Inc, Celgene Corporation, Eisai Co. Ltd, and Sunesis Pharmaceuticals rule the present market for acute myeloid leukemia drugs; whereas Ambit Bioscience is expected to capture major share of the market by 2020.
Scope of the report
This myeloid leukemia therapeutics market research report evaluates the therapeutics market of acute myeloid leukemia in G8 countries with respect to the current and pipeline drugs and regimens. It analyzes geography; forecasting revenue, and trends in each of the following submarkets:
For more information kindly visit :
Acute Myeloid Leukemia Therapeutics Market (2010-2020) (Pipeline Assessment & Market Forecast in G8 Countries)
Contact us at:
Bharat Book Bureau
Tel: 09221586973
Email: info@bharatbook.com
Website: http://www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Acute Myeloid Leukemia Therapeutics Market (2010-2020) (Pipeline Assessment & Market Forecast in G8 Countries)
Bharatbook added a new report on " Acute Myeloid Leukemia Therapeutics Market (2010-2020) (Pipeline Assessment & Market Forecast in G8 Countries) " which gives an overview, Demand, Supply Trends and industry analysis reports.